212 PB GRPR
Alternative Names: 212-PB-GRPR; Lead-212-GPRPLatest Information Update: 17 Feb 2023
At a glance
- Originator Orano Med
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Lead radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 12 Jan 2023 Preclinical trials in Solid tumours in USA (Parenteral), prior to January 2023 (Orano Med pipeline, January 2023)
- 12 Jan 2023 Orano Med plans a phase I trial for Solid tumours in the USA (NCT05283330)
- 04 Jan 2023 Phase-I clinical trials in Solid tumours (Metastatic disease, Locally recurrent, In adults, In the elderly) at unspecified location (Parenteral) (NCT05283330)